Patent: 10,322,104
Summary for Patent: 10,322,104
| Title: | Disulfur bridge linkers for conjugation of a cell-binding molecule |
| Abstract: | The present invention relates to novel disulfur bridge linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule. The invention also relates to methods of making such linkers, and of using such linkers in making homogeneous conjugates, as well as of application of the conjugates in treatment of cancers, infections and autoimmune disorders. |
| Inventor(s): | Zhao; Robert Yongxin (Lexington, MA) |
| Assignee: | HANGZHOU DAC BIOTECH CO., LTD. (Hangzhou, CN) |
| Application Number: | 15/479,859 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,322,104
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | August 24, 1998 | ⤷ Start Trial | 2037-04-05 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | September 25, 1998 | ⤷ Start Trial | 2037-04-05 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | February 10, 2017 | ⤷ Start Trial | 2037-04-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
